Everlife Biomed
Latest round
- Series A
Last raised
- Jun 2025
Total raised
- Undisclosed
Investors
- 3
About Everlife Biomed
Established in 2018 and based in Beijing, China, Everlife Biomed is a biotechnology company that engages in the research and development of Human-derived immune-exempt cell therapy products. In February 2019, it signed a cooperation agreement with Tsinghua University Medical School. In April 2021, it signed the first clinical experimental hospital.D. from the Tsinghua-Peking University Life Sciences Joint Center and the main inventor of the Sertoli cell core patent. The chief scientist officer, Jiakui Ji, is a professor at Tsinghua University, an expert in the field of stem cell differentiation, and the main inventor of the domestic patent of immune cell induction technology and PCT patent. The company's products can be categorized into rheumatoid arthritis cell injection, immune-exempt artificial pancreas, and assisted reproductive testing systems. It has developed immune-exempt drugs to protect transplanted cells or tissues from host attack, to treat autoimmune diseases, or as a carrier for transplanted cells. The company generates revenue from clinical-stage cell therapy products, licensing of immune-exempt technologies, and specialized diagnostic systems in reproductive and autoimmune health.
Who invested in Everlife Biomed
3 investors across 2 rounds
See all investors in Everlife Biomed
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Everlife Biomed
Who invested in Everlife Biomed?
Everlife Biomed has 3 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Everlife Biomed raised?
Everlife Biomed has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Everlife Biomed last raise money?
Everlife Biomed's most recent round on record is a Series A, in Jun 2025.
What does Everlife Biomed do?
Established in 2018 and based in Beijing, China, Everlife Biomed is a biotechnology company that engages in the research and development of Human-derived immune-exempt cell therapy products.
Where is Everlife Biomed headquartered?
Everlife Biomed is headquartered in Beijing, China.
Which VCs invest in companies like Everlife Biomed?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Everlife Biomed's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Everlife Biomed? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.